205 related articles for article (PubMed ID: 32430490)
21. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
Li TK; Houghton PJ; Desai SD; Daroui P; Liu AA; Hars ES; Ruchelman AL; LaVoie EJ; Liu LF
Cancer Res; 2003 Dec; 63(23):8400-7. PubMed ID: 14679002
[TBL] [Abstract][Full Text] [Related]
22. New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis.
Tian QT; Ding CY; Song SS; Wang YQ; Zhang A; Miao ZH
Biochem Pharmacol; 2018 Aug; 154():255-264. PubMed ID: 29753750
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.
Beck DE; Lv W; Abdelmalak M; Plescia CB; Agama K; Marchand C; Pommier Y; Cushman M
Bioorg Med Chem; 2016 Apr; 24(7):1469-79. PubMed ID: 26906474
[TBL] [Abstract][Full Text] [Related]
24. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
Zhao H; Rybak P; Dobrucki J; Traganos F; Darzynkiewicz Z
Cytometry A; 2012 Jan; 81(1):45-51. PubMed ID: 22140093
[TBL] [Abstract][Full Text] [Related]
25. Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.
Kinders RJ; Hollingshead M; Lawrence S; Ji J; Tabb B; Bonner WM; Pommier Y; Rubinstein L; Evrard YA; Parchment RE; Tomaszewski J; Doroshow JH;
Clin Cancer Res; 2010 Nov; 16(22):5447-57. PubMed ID: 20924131
[TBL] [Abstract][Full Text] [Related]
26. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
27. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
Pommier Y
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
[TBL] [Abstract][Full Text] [Related]
28. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
Mol Autism; 2018; 9():45. PubMed ID: 30140420
[TBL] [Abstract][Full Text] [Related]
29. Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential.
Laev SS; Salakhutdinov NF; Lavrik OI
Bioorg Med Chem; 2016 Nov; 24(21):5017-5027. PubMed ID: 27687971
[TBL] [Abstract][Full Text] [Related]
30. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Coussy F; El-Botty R; Château-Joubert S; Dahmani A; Montaudon E; Leboucher S; Morisset L; Painsec P; Sourd L; Huguet L; Nemati F; Servely JL; Larcher T; Vacher S; Briaux A; Reyes C; La Rosa P; Lucotte G; Popova T; Foidart P; Sounni NE; Noel A; Decaudin D; Fuhrmann L; Salomon A; Reyal F; Mueller C; Ter Brugge P; Jonkers J; Poupon MF; Stern MH; Bièche I; Pommier Y; Marangoni E
Sci Transl Med; 2020 Feb; 12(531):. PubMed ID: 32075943
[TBL] [Abstract][Full Text] [Related]
31. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
Cushman M; Jayaraman M; Vroman JA; Fukunaga AK; Fox BM; Kohlhagen G; Strumberg D; Pommier Y
J Med Chem; 2000 Oct; 43(20):3688-98. PubMed ID: 11020283
[TBL] [Abstract][Full Text] [Related]
33. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors.
Nguyen TX; Abdelmalak M; Marchand C; Agama K; Pommier Y; Cushman M
J Med Chem; 2015 Apr; 58(7):3188-208. PubMed ID: 25811317
[TBL] [Abstract][Full Text] [Related]
35. TDP2/TTRAP is the major 5'-tyrosyl DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage.
Zeng Z; Cortés-Ledesma F; El Khamisy SF; Caldecott KW
J Biol Chem; 2011 Jan; 286(1):403-9. PubMed ID: 21030584
[TBL] [Abstract][Full Text] [Related]
36. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
37. Repair of trapped topoisomerase II covalent cleavage complexes: Novel proteasome-independent mechanisms.
Tsuda M; Kitamasu K; Hosokawa S; Nakano T; Ide H
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):170-184. PubMed ID: 31608820
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
Morrell A; Jayaraman M; Nagarajan M; Fox BM; Meckley MR; Ioanoviciu A; Pommier Y; Antony S; Hollingshead M; Cushman M
Bioorg Med Chem Lett; 2006 Aug; 16(16):4395-9. PubMed ID: 16750365
[TBL] [Abstract][Full Text] [Related]
39. [Molecular determinants of response to topoisomerase I inhibitors].
Pourquier P; Lansiaux A
Bull Cancer; 2011 Nov; 98(11):1287-98. PubMed ID: 22049384
[TBL] [Abstract][Full Text] [Related]
40. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
